Attractive valuation + promising growth prospects: UBS Group AG upgrades CVS Health (CVS.US) to "buy" rating.

19/08/2025

UBS has upgraded its rating on the stock of American drug retailer CVS Health from "hold" to "buy," and raised its target price from $67 to $79.

UBS Group AG has upgraded its stock rating on American drugstore retailer CVS Health (CVS.US) from "hold" to "buy," and raised its target price from $67 to $79. This target price represents an almost 13% increase from the stock's closing price of $70.17 on Monday. UBS Group AG stated that CVS Health has attractive valuation and good growth prospects. Analyst Kevin Caliendo mentioned that the company has performed well in the past two quarters, and "preliminary signs indicate a smooth recovery in the Healthcare Benefits (HCB) segment." The analyst also praised the company's healthcare insurance discount program. He added, "CVS' benefit cuts and associated utilization assumptions for the HCB plan for this plan year have proved to be accurate (confidence is high given significant progress last year), which gives us confidence in the company's forecasting and management trends."

ZCLOUD TECH CON (09900) issued 2.604 billion shares due to stock split.

JIANGSU EXPRESS (00177) has completed the issuance of 500 million yuan in short-term financing notes.

REMEGEN (09995): The National Medical Products Administration Drug Evaluation Center has awarded breakthrough therapy designation to RC148 for the treatment of non-small cell lung cancer.

ZCLOUD TECH CON (09900) issued 2.604 billion shares due to stock split.

JIANGSU EXPRESS (00177) has completed the issuance of 500 million yuan in short-term financing notes.

REMEGEN (09995): The National Medical Products Administration Drug Evaluation Center has awarded breakthrough therapy designation to RC148 for the treatment of non-small cell lung cancer.